EMA publishes risk levels of experts based on industry connections
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has published the "risk levels" of all the experts that are involved in its drug regulatory activities, based on the interests they have declared in relation to the pharmaceutical industry. The risk levels are used together with the declarations of interests to determine the extent to which a particular expert can take part in the agency's drug authorisation and surveillance operations.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.